In genetically challenged women with decreased ER expression and/or E2-refractory ERs, the facilitation of ER production via ESR1mRNA treatment increases the expression of estrogen-regulated genes, preventing the development of cancer in the breasts and ovaries. Here, ESR1 is linked to cancer.